New and old prognostic factors in polycythemia vera

Passamonti F, Rumi E, Pungolino E, et al.: Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004, 117:755–761.

Passamonti F, Malabarba L, Orlandi E, et al.: Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003, 88:13–18.

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med 1995, 123:656–664.

Kralovics R, Passamonti F, Buser AS, et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779–1790.

Pietra D, Li S, Brisci A, et al.: Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008, 111:1686–1689.

Scott LM, Tong W, Levine RL, et al.: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459–468.

Landolfi R, Di Gennaro L, Barbui T, et al.: Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007, 109:2446–2452.

Passamonti F, Rumi E, Caramella M, et al.: A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008, 111:3383–3387.

Gangat N, Strand J, Li CY, et al.: Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007, 138:354–358.

Rozman C, Giralt M, Feliu E, et al.: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991, 67:2658–2663.

Kiladjian JJ, Gardin C, Renoux M, et al.: Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J 2003, 4:198–207.

Ania BJ, Suman VJ, Sobell JL, et al.: Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935–1989. Am J Hematol 1994, 47:89–93.

Najean Y, Mugnier P, Dresch C, Rain JD: Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol 1987, 67:285–291.

Perea G, Remacha A, Besses C, et al.: Is polycythemia vera a serious disease in young adults? Haematologica 2001, 86:543–544.

Marchioli R, Finazzi G, Landolfi R, et al.: Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005, 23:2224–2232.

Mesa RA, Verstovsek S, Cervantes F, et al.: Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the International Working Group for Myelofibrosis Research And Treatment (IWG-MRT). Leuk Res 2007, 31:737–740.

Barosi G, Mesa RA, Thiele J, et al.: Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008, 22:437–438.

Passamonti F, Rumi E, Pietra D, et al.: Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006, 107:3676–3682.

Passamonti F, Vanelli L, Malabarba L, et al.: Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders Haematologica 2003, 88:1123–1129.

Deeg HJ, Gooley TA, Flowers ME, et al.: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003, 102:3912–3918.

Rondelli D, Barosi G, Bacigalupo A, et al.: Allogeneic hematopoietic stem-cell transplantation with reducedintensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 105:4115–4119.

Pardanani A: JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008, 22:23–30.

Passamonti F, Rumi E, Arcaini L, et al.: Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer 2005, 104:1032–1036.

Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms Blood 2002, 100:2292–2302.

Tam CS, Nussenzveig RM, Popat U, et al.: The natural history and treatment outcome of blast phase BCRABL [negative] myeloproliferative neoplasms. Blood 2008, 112:1628–1637.

Elliott MA, Tefferi A: Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005, 128:275–290.

Passamonti F, Brusamolino E, Lazzarino M, et al.: Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 2000, 85:1011–1018.

Berk PD, Goldberg JD, Donovan PB, et al.: Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986, 23:132–143.

Landolfi R, Marchioli R, Kutti J, et al.: Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004, 350:114–124.

Di Nisio M, Barbui T, Di Gennaro L, et al.: The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007, 136:249–259.

Falanga A, Marchetti M, Evangelista V, et al.: Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000, 96:4261–4266.

Falanga A, Marchetti M, Vignoli A, et al.: V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007, 35:702–711.

Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al.: Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006, 91:169–175.

Vannucchi AM, Antonioli E, Guglielmelli P, et al.: Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110:840–846.

Tefferi A, Lasho TL, Schwager SM, et al.: The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006, 106:631–635.

Vannucchi AM, Antonioli E, Guglielmelli P, et al.: Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007, 21:1952–1959.

Tefferi A, Strand JJ, Lasho TL, et al.: Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007, 21:2074–2075.

Lacout C, Pisani DF, Tulliez M, et al.: JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108:1652–1660.

Passamonti F, Rumi E, Pietra D, et al.: JAK2 (V617F) mutation burden, phenotype, and clinical course of chronic myeloproliferative disorders [abstract]. Haematologica 2007, 92(s1):243.

Finazzi G, Caruso V, Marchioli R, et al.: Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005, 105:2664–2670.

Rumi E, Passamonti F, Della Porta MG, et al.: Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007, 25:5630–5635.

Theocharides A, Boissinot M, Girodon F, et al.: Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007, 110:375–379.

Campbell PJ, Baxter EJ, Beer PA, et al.: Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006, 108:3548–3555.

Gangat N, Strand J, Lasho TL, et al.: Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 2008, 80:197–200.

Spivak JL: Polycythemia vera: myths, mechanisms, and management. Blood 2002, 100:4272–4290.

Dingli D, Schwager SM, Mesa RA, et al.: Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 2006, 106:1985–1989.